Please assess the completion status of the following clinical trial:

Trial Title: The Clinical Efficacy of DFPP in Patients With AAGN

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* a diagnosis of ANCA associated vasculitis(AAV), using criteria adapted from the disease definitions of the Chapel Hill consensus conference~* serum positive ANCA and the ANCA level ≥100 relative unit/ml~* with renal involvement and serum creatinine≥3 mg/dl~* written informed consent had been provided.~Exclusion Criteria:~* other secondary vasculitis~* anti-glomerular basement membrane(GBM) positive~* severe infection; hepatitis B antigenemia, anti- hepatitis C virus~* immunodeficiency; or immunoglobulin G(IgG)\<2g/l~* life threatening~* renal biopsy show globally sclerotic glomeruli\>60% and normal glomeruli\<10%~* need renal replacement therapy for more than 4w~* received large dose of methylprednisolone(MP),CTX,mycophenolate mofetil(MMF), plasmapheresis or intravenous immunoglobulin(IVIg) therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DFPP&CTX (Type: EXPERIMENTAL): double filtration plasmapheresis(DFPP) combined with intravenous cyclophosphamide (IV-CTX) pulse therapy in addition(DFPP\&CTX)
- cyclophosphamide (Type: ACTIVE_COMPARATOR): cyclophosphamide(CTX) pulse therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).